Naloxone hydrochloride manufacturers

The company is a pharmaceutical manufacturer engaged in the development, production and export of a range of pharmaceutical products across key therapeutic segments including oncology, critical care and lifesaving medicines, operating with certified manufacturing capabilities and global distribution networks to supply these pharmaceutical products to international healthcare markets.

Established in 2017, this pharmaceutical manufacturer specializes in developing and producing affordable, high-quality complex generics. As a CTD dossier owner and manufacturer, it holds multiple GMP certifications, including approvals from the US FDA, DEA, WHO GMP, and ISO, ensuring compliance with stringent international quality standards. The company operates three manufacturing facilities, including a US FDA-approved formulation plant and an API & intermediates manufacturing plant, with 14 manufacturing lines dedicated to emerging markets. Its diverse product portfolio encompasses tablets, capsules, liquids, dry syrups, oral rehydration solutions, active pharmaceutical ingredients, and critical care injectables, such as antibiotics, antifungals, and blood line products. With a presence in 49 countries and over 270 commercial products, the manufacturer is committed to enhancing global healthcare accessibility

Established in 2013, this manufacturer specializes in producing high-quality generic formulations in the oncology and hormonal segments. As a CTD dossier owner and manufacturer, it adheres to strict GMP guidelines, ensuring its products meet rigorous international standards. The manufacturer operates cutting-edge production facilities that are designed to meet the demands of global markets. As a CTD dossier owner and manufacturer, it distributes its products across various countries, reinforcing its commitment to enhancing patient care globally.